|Abstract:||(S)-alpha-ethyl-2-oxo-1-pyrrolidineacetamide, its preparation and pharmaceutical compositions containing the same. It can be prepared either by reacting (S)-alpha-ethyl-2-oxo-1-pyrrolidineacetic acid successively with an alkyl haloformate and with ammonia, or, by cyclizing an (S)-2-amino-butanamide of the formula X--CH.sub.2 CH.sub.2 --Y--NHCH(C.sub.2 H.sub.5)CONH.sub.2 wherein Y is a --CH.sub.2 -- radical when X represents a ZOOC-- radical and Y is a --CO-- radical when X represents a HalCH.sub.2 -- radical, Z being a C.sub.1 -C.sub.4 alkyl radical and Hal a halogen atom. This laevorotatory enantiomer has been found to have significantly higher protective activity against hypoxia and ischemia than the corresponding racemate.|
|Inventor(s):||Gobert; Jean (Brussels, BE), Geerts; Jean-Pierre (Leglise, BE), Bodson; Guy (Bellefontaine, BE)|
|Assignee:||U C B Societe Anonyme (Brussels, BE)|
Patent Claim Types:|
see list of patent claims
|Foriegn Application Priority Data|
|Foreign Country||Foreign Patent Number||Foreign Patent Date|
|United Kingdom||8412357||May 15, 1984|
|Country||Document Number||Estimated Expiration||Supplementary Protection Certificate||SPC Country||SPC Expiration|
| This preview shows a limited data set|
Subscribe for full access, or try a Trial
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.